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OBJECTIVES We sought to determine whether eptifibatide decreases the incidence of in-laboratory
angiographic complications and to determine the relationship of angiographically evident
complications to elevations of creatine kinase-MB (CK-MB) enzyme levels during percuta-
neous coronary intervention.
BACKGROUND In the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
(ESPRIT) trial, eptifibatide during coronary intervention was associated with decreased
ischemic complications at 48 h and 30 days.
METHODS Patients (n 5 2,064) were randomized to placebo versus eptifibatide (two 180 mg/kg boluses
10 min apart and as a continuous infusion of 2 mg/kg per min) during percutaneous coronary
stenting. Angiographic complications including major dissection, distal embolization, resid-
ual thrombus, abrupt closure, residual stenosis .50% and side-branch occlusion were
prospectively recorded by the operator. Creatine kinase-MB levels were measured after the
procedure and every 6 h thereafter. The incidence of angiographic complications and CK-MB
elevation was determined for eptifibatide versus placebo groups.
RESULTS Eptifibatide-treated patients demonstrated nonsignificant trends toward fewer angiographic
complications (10 vs. 12% for placebo patients, p 5 0.13) and, for patients with angiographic
complications, fewer subsequent CK-MB elevations (43 vs. 50% for placebo patients, p 5
0.31). In patients without any angiographic complications, the incidence of CK-MB elevation
.3 times the normal was 7% with placebo and 4% with eptifibatide (p 5 0.003).
CONCLUSIONS Eptifibatide during nonurgent coronary stent intervention only minimally (and insignifi-
cantly) reduces the incidence of angiographic complications and subsequent CK-MB
elevations in patients developing an angiographic complication. The greater effect is to reduce
myocardial infarction in patients undergoing otherwise uneventful coronary stent implanta-
tion as well as in the overall study population. (J Am Coll Cardiol 2001;38:653–8) © 2001
by the American College of Cardiology
Procedural complications during coronary intervention are
often accompanied by elevation of creatine kinase-MB
(CK-MB) enzyme levels. Several studies have associated
transient closure, side-branch compromise, dissection, distal
embolism and other adverse events during coronary inter-
vention with elevated CK-MB enzymes (1–9). Elevated
CK-MB enzymes after coronary intervention are associated
with increased long-term risks of cardiac events (1,2,4–9).
The Integrilin to Minimize Platelet Aggregation and
Coronary Thrombosis (IMPACT) II trial demonstrated
that the platelet glycoprotein (GP) IIb/IIIa receptor inhib-
itor eptifibatide (Integrilin, COR Therapeutics Inc., South
San Francisco, California) decreases ischemic complications
of coronary intervention (10). These findings were con-
firmed in the Enhanced Suppression of the Platelet IIb/IIIa
Receptor with Integrilin Therapy (ESPRIT) trial (11).
Neither study (10,11) identified how GP IIb/IIIa inhibitors
prevent ischemic complications or whether reduction of
angiographic complications during coronary intervention
plays a role. We studied angiographic complications during
coronary intervention in the ESPRIT trial to determine if
they were less frequent in eptifibatide-treated patients.
METHODS
The ESPRIT trial. The ESPRIT trial was a multicenter,
randomized, double-blind, parallel group, placebo-controlled,
crossover-permitted clinical trial in North America. The
study design and rationale have been previously reported
(12). Only those patients scheduled to undergo percutane-
ous coronary intervention with stent implantation in a
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native coronary artery were eligible. Patients were excluded
if the treating physician deemed that pretreatment with a
GP IIb/IIIa inhibitor was warranted. Other exclusion cri-
teria included myocardial infarction (MI) within 24 h before
randomization, history of bleeding diathesis or chronic
warfarin therapy.
Patients (n 5 2,064) were randomized to receive either
placebo or eptifibatide in a 1:1 ratio, started immediately
before the coronary intervention. Eptifibatide was given as
two 180 mg/kg boluses 10 min apart and as a continuous
infusion of 2 mg/kg per min (or 1 mg/kg per min in patients
with serum creatinine .2 mg/dl) started at the same time as
the first bolus and continuing for 18 h to 24 h. Essentially,
all patients received concomitant aspirin, and a weight-
adjusted heparin regimen was recommended (initial bolus of
60 U/kg) with a target activated clotting time between 200 s
and 300 s. Heparin infusion after the coronary intervention
was strongly discouraged. Treatment with ticlopidine or
clopidogrel was stipulated per protocol on the day of the
procedure but not permitted before then; the choice of
loading dose was left to the treating physician.
After the coronary intervention, the investigator recorded
any angiographic complications on case report forms. Cre-
atine kinase and CK-MB enzymes were obtained immedi-
ately after the procedure and every 6 h for the first 24 h (or
until discharge) and were analyzed by a central core labo-
ratory.
End points. Angiographic complications are listed in Ta-
ble 1. The primary end point of the ESPRIT trial was the
composite of death, MI, urgent target vessel revasculariza-
tion and thrombotic “bail-out” GP IIb/IIIa therapy within
48 h of randomization. The key secondary end point was the
composite of death, MI and urgent target vessel revascular-
ization at 30 days. End point MIs included those confirmed
as MI after adjudication by a clinical events committee and
those identified by elevation of CK/CK-MB isoenzymes to
$3 times the upper limit of normal on two occasions
measured 6 h apart.
Statistical analysis. Data on angiographic complications
were available and were analyzed for 2,062 patients. Patients
were excluded from subsequent CK and CK-MB analyses if
no postintervention CK or CK-MB measurements were
available (n 5 180) or if baseline CK or CK-MB (n 5 221)
was elevated (due to a recent MI).
The data evaluated in this study include categorical,
ordered categorical and continuous variables. Categorical
variables are presented as frequencies with the percentages
of patients with the characteristic. Continuous measures are
presented as means with SD and medians with 25th and
75th percentiles and ranges. The chi-square test was used to
evaluate associations between nonordered categorical vari-
ables. For dichotomous variables, the p value from the
Fisher exact test is provided where expected cell frequencies
were too low for the chi-square test. For the ordered
categorical and continuous variables, the Wilcoxon rank-
sum test was used. A p value of ,0.05 was considered
statistically significant.
RESULTS
Baseline clinical characteristics. Patients with angio-
graphic complications and patients without such events
were similar with respect to 14 baseline characteristics
including atherosclerotic risk factors, prior cardiac events,
gender, age, weight and presenting syndrome. Patients with
and without angiographic complications also had similar
medications before coronary intervention, including similar
use of aspirin, thienopyridines and heparin.
Baseline lesion characteristics. The incidence of angio-
graphic complications was similar in all three major coro-
nary arteries. Patients with angiographic complications
(compared with those without angiographic complications)
were more likely to have Thrombolysis In Myocardial
Infarction flow grade 0/1 (15 vs. 6%, p 5 0.001), thrombus
(11 vs. 4%, p 5 0.001) and severe stenosis (mean 90 vs.
86%, p , 0.001) at the start of the intervention.
Procedural characteristics. Angiographic complications
were associated with longer procedure durations; median
time was 1.72 (1.32, 2.25) h for patients with events versus
1.3 (0.97, 1.73) h for patients without events (p 5 0.001).
Maximum procedural activated clotting times were similar
for patients with (280 [232, 309] s) and without events (264
[233, 304], p 5 0.47).
Eptifibatide and angiographic complications. An angio-
graphic complication occurred in 11% of 2,062 patients who
underwent coronary intervention (Table 1). There was a
Abbreviations and Acronyms
CK-MB 5 creatine kinase-MB
ESPRIT 5 Enhanced Suppression of the Platelet IIb/
IIIa Receptor with Integrilin Therapy trial
GP 5 glycoprotein
IMPACT 5 Integrilin to Minimize Platelet Aggregation
and Coronary Thrombosis trial
MI 5 myocardial infarction
Table 1. Incidence of Angiographic Complications
Angiographic
Complication
Eptifibatide
(n 5 1,039)
Placebo
(n 5 1,023)
p
Value
Combined
(n 5 2,062)
Major dissection 40 (3.9%) 37 (3.6%) 0.78 77 (3.7%)
Abrupt closure 10 (1.0%) 11 (1.1%) 0.80 21 (1.0%)
No reflow 15 (1.4%) 12 (1.2%) 0.29 27 (1.3%)
Thrombus formation 9 (0.9%) 16 (1.6%) 0.15 25 (1.2%)
Side-branch closure 35 (3.4%) 50 (4.9%) 0.08 85 (4.1%)
Distal embolization 10 (1.0%) 5 (0.5%) 0.21 15 (0.7%)
Residual stenosis .50% 23 (2.2%) 26 (2.5%) 0.22 49 (2.4%)
TIMI grade flow ,3 19 (1.8%) 25 (2.5%) 0.71 44 (2.1%)
Residual thrombus 5 (0.5%) 10 (1.0%) 0.18 15 (0.7%)
Any of the above 105 (10.1%) 125 (12.2%) 0.13 230 (11.15%)
TIMI 5 Thrombolysis In Myocardial Infarction.
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trend toward fewer events in patients treated with eptifi-
batide (10.1 vs. 12.2% placebo, p 5 0.13). There were
nonsignificant reductions in thrombus formation (p 5
0.15), residual thrombus (p 5 0.18) and side-branch occlu-
sion (p 5 0.08) in eptifibatide-treated patients. The results
were almost identical when analyses were repeated on a
1,661-patient subset that excluded all patients with CK or
CK-MB measurements that were either elevated at baseline
or not performed after the procedure.
Extent of enzyme elevation associated with angiographic
complications. The distributions of CK and CK-MB en-
zymes were studied in patients with normal levels at
baseline. Elevated CK-MB levels were found in 56% of
patients with angiographic complications and in 26% of
patients without such events (Table 2). Creatine kinase-MB
levels .3 times the normal were observed in 25% of adverse
event patients versus 9% of those without such events (p ,
0.01).
Incidence of CK-MB elevation in patients with angio-
graphic complications. Eptifibatide did not significantly
decrease the incidence of any degree of CK-MB elevation
above upper normal limits in either the group of patients
with or the group without angiographic complications
(Table 3). Creatine kinase-MB enzyme levels .3 times the
normal upper limits occurred in 21% to 22% of patients with
angiographic complications and in 4% to 7% of patients
without such events. Only in patients without adverse
events was there a difference between eptifibatide and
placebo patients (4 vs. 7%, p 5 0.003). There was a
consistent trend toward fewer CK-MB elevations above
normal in eptifibatide-treated patients, but this trend was
less consistent for CK-MB elevations .3 times the normal
limits.
Parallel analyses involving CK enzyme levels produced
similar results (Table 4). There were no differences in CK
elevation between eptifibatide and placebo patients with
angiographic complications. In patients without angio-
graphic complications, fewer eptifibatide patients had CK
elevation above normal (6 vs. 9% in placebo patients, p 5
0.033).
Angiographic complications and clinical end points.
Patients with angiographic complications had a significantly
higher incidence of the composite primary clinical end point
at 48 h than patients without angiographic complications
(26 vs. 5%, p 5 0.001; Table 5). This association persisted
at 30 days. Since death and revascularization procedures
were infrequent, most of these differences were due to a
higher incidence of MI in patients with angiographic
complications. A parallel analysis excluded 180 patients for
whom CK or CK-MB data were missing, with nearly
identical results observed for the remaining 1,881 patients.
Table 2. Distribution of CK-MB and CK Enzyme Levels in Patients With Versus Without
Angiographic Complications: Patients With Elevated Baseline CK or CK-MB and Patients
With No Available Postprocedure CK or CK-MB Measurements Were Excluded
Enzyme Elevation
(% of Upper Normal Limits)
CK-MB CK
Angiographic
Complication
(n 5 183)
No Angiographic
Complication
(n 5 1,478)
Angiographic
Complication
(n 5 183)
No Angiographic
Complication
(n 5 1,478)
0%–100% 84 (46%) 1,092 (74%) 136 (74%) 1,369 (93%)
100%–300% 53 (29%) 290 (20%) 32 (18%) 98 (6%)
300%–500% 14 (8%) 49 (3%) 11 (6%) 6 (, 1%)
500%–1,000% 15 (8%) 35 (2%) 4 (2%) 5 (, 1%)
.1,000% 17 (9%) 12 (, 1%) 0 (0%) 0 (0%)
CK-MB 5 creatine kinase-myocardial band.
Table 3. Incidence of CK-MB Enzyme Elevation Among Patients With Angiographic Complications (Excluding Patients With
Abnormal CK-MB Enzyme Elevation Immediately Before or During Procedure)
Angiographic Complication
CK-MB >13 Normal
p Value*
CK-MB >33 Normal
p Value*Eptifibatide Placebo Eptifibatide Placebo
Major dissection 16/40 (40%) 19/37 (51%) 0.317 5/40 (13%) 8/37 (22%) 0.285
Distal embolization 4/10 (40%) 3/5 (60%) 0.608 3/10 (30%) 1/5 (20%) 1.000
Residual thrombus 3/5 (60%) 8/10 (80%) 0.560 2/5 (40%) 4/10 (40%) 1.000
Abrupt closure 4/10 (40%) 6/11 (55%) 0.670 2/10 (20%) 3/11 (27%) 1.000
Residual stenosis .50% 6/23 (26%) 11/26 (42%) 0.231 1/23 (4%) 7/26 (27%) 0.052
Side-branch occlusion 18/35 (51%) 27/50 (54%) 0.815 11/35 (31%) 14/50 (28%) 0.733
TIMI grade ,3 7/19 (37%) 12/25 (48%) 0.458 2/19 (11%) 7/25 (28%) 0.260
Thrombus formation and no reflow 10/24 (42%) 19/28 (68%) 0.057 4/24 (17%) 12/28 (43%) 0.038
Any angiographic complication 45/105 (43%) 62/125 (50%) 0.31 22/105 (21%) 27/125 (22%) 0.91
No angiographic complications 197/934 (21%) 201/898 (22%) 0.51 35/934 (4%) 61/898 (7%) 0.003
*Multiple comparisons and small numbers of individual angiographic complications increase the likelihood that p values ,0.05 will occur by chance. Numerator is the number
of patients with CK-MB level elevation in this treatment arm who have the complication of interest. Denominator is the number of patients with the complication.
CK-MB 5 creatine kinase-myocardial band; TIMI 5 Thrombolysis In Myocardial Infarction.
655JACC Vol. 38, No. 3, 2001 Blankenship et al.
September 2001:653–8 PTCA Complications With Eptifibatide
DISCUSSION
The critical findings of this study are several. First, there
were nonsignificant trends toward the reduction of several
individual angiographic complications in eptifibatide-
treated patients and in the overall incidence of angiographic
complications among patients undergoing coronary inter-
vention in the ESPRIT trial. However, the 16% relative
reduction in angiographic complications observed in the
eptifibatide arm did not reach statistical significance. In
contrast, eptifibatide decreased the relative incidence of
death or MI at 48 h by 43% (p 5 0.0017). Thus, prevention
of angiographic complications must contribute only mod-
estly to the clinical benefit imparted by eptifibatide treat-
ment.
Eptifibatide’s failure to prevent CK-MB elevation in
patients with angiographic complications. We expected
that eptifibatide would prevent CK-MB elevations among
patients with angiographic complications; however, the
relative reduction associated with eptifibatide in these pa-
tients was only 14% for CK-MB .1 times the normal limit
and 5% for CK-MB .3 times the normal limits. Neither
reduction approached statistical significance. We conclude
that limiting CK-MB elevations in patients with angio-
graphic complications contributes only modestly to the
overall clinical effect of eptifibatide.
Eptifibatide’s effects on CK-MB in patients without
angiographic complications. An additional important
finding is that the largest eptifibatide effect observed in this
study was in patients without angiographic complications.
The incidence of large CK-MB elevations (.3 times the
normal) decreased from 7% in placebo patients to 4% in
eptifibatide patients (42% relative reduction, p 5 0.003).
Because most of the patients in this study (89%) were free of
angiographic complications, this relatively small reduction
had the largest impact on the number of patients with
ischemic end points.
Angiographic complications and ischemic events. Be-
cause eptifibatide decreased ischemic complications of in-
tervention in the ESPRIT trial but did not significantly
decrease angiographic complications, we questioned
whether these two events were associated. Patients with
angiographic complications had a fivefold higher risk of
a subsequent ischemic event within the first 48 h after
coronary intervention (p 5 0.001). The 11% of patients
with angiographic complications accounted for almost 40%
of ischemic events by 48 h, suggesting that angiographic
complications are associated with subsequent ischemic
events. Because both angiographic complications and isch-
emic events occur after randomization, no statistical infer-
ences can be made regarding causation.
Comparison of effects of eptifibatide and placebo on
angiographic complications and CK-MB elevations. To
compare the effects of eptifibatide, we extrapolated the data
reported here to imaginary cohorts of 1,000 patients (Table
6). This analysis is dependent upon the assumption that the
effects observed in this report have a high degree of
precision. Given this caveat, eptifibatide would decrease the
incidence of CK-MB elevation .3 times the normal from
86 patients per 1,000 in placebo patients to 55 patients per
1,000 in eptifibatide-treated patients. This is consistent
with the ESPRIT trial finding that death or MI occurred in
8.6% of placebo patients and 4.9% of eptifibatide patients.
Table 4. Incidence of CK Enzyme Elevation Among Patients With Angiographic Complications Excluding Patients With Abnormal
CK-MB Enzyme Elevation Before or During Procedure
Angiographic Complication
CK >13 Normal
p Value*
CK >33 Normal
p Value*Eptifibatide Placebo Eptifibatide Placebo
Major dissection 5/40 (13%) 9/37 (24%) 0.177 2/40 (5%) 2/37 (5%) 1.000
Distal embolization 2/10 (20%) 1/5 (20%) 1.000 0/10 (0%) 1/5 (20%) 0.375
Residual thrombus 2/5 (40%) 4/10 (40%) 1.000 2/5 (40%) 2/10 (20%) 0.560
Abrupt closure 1/10 (10%) 5/11 (45%) 0.149 1/10 (10%) 2/11 (18%) 1.000
Residual stenosis .50% 2/23 (9%) 7/26 (27%) 0.145 0/23 (0%) 3/26 (12%) 0.237
Side-branch occlusion 13/35 (37%) 15/50 (30%) 0.492 4/35 (11%) 6/50 (12%) 1.000
TIMI grade ,3 3/19 (16%) 8/12 (67%) 0.007 0/19 (0%) 4/25 (16) 0.122
Thrombus formation and no reflow 4/24 (17%) 8/28 (29%) 0.305 3/24 (13%) 3/28 (11%) 1.000
Any angiographic complication 23/105 (22%) 28/125 (22%) 0.93 7/105 (7%) 10/125 (8%) 0.70
No angiographic complications 56/934 (6%) 77/898 (9%) 0.033 5/934 (0.5%) 8/898 (0.9%) 0.37
*Multiple comparisons and small numbers of individual angiographic complications increase the likelihood that p values ,0.05 will occur by chance. Numerator is the number
of patients with CK-MB level in this treatment arm who have the complication of interest. Denominator is the number of patients with the complication.
CK-MB 5 creatine kinase-myocardial band; TIMI 5 Thrombolysis In Myocardial Infarction.
Table 5. Clinical End Points in Patients With Versus Without
Angiographic Complications During Coronary Intervention
Clinical End Point
Angiographic Complication
Any
(n 5 230)
None
(n 5 1,832) p Value
48 h
Death 0 (0%) 3 (0.16%) 1.000*
Myocardial infarction 55 (23.9%) 93 (5.1%) 0.001
Revascularization 9 (3.9%) 7 (0.4%) , 0.001
Any of the above 60 (26.1%) 97 (5.3%) 0.001
30 days
Death 1 (0.4%) 9 (0.5%) 0.638
Myocardial infarction 55 (23.9%) 108 (5.9%) 0.001
Revascularization 10 (4.4%) 18 (1.0%) , 0.001
Any of the above 63 (26.1%) 118 (6.4%) 0.001
*For cells with low expected frequencies, p value of Fisher exact test is reported.
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Most notably, of 31 CK-MB elevations prevented by
eptifibatide, 26 (84%) would occur in patients without
angiographic complications. Only five would occur from the
prevention of angiographic complications or the prevention
of CK-MB elevation in those with angiographic complica-
tions.
Mechanisms of angiographic complications and CK-MB
elevations. Some of the angiographic complications in-
cluded in this study may be primarily mechanical (e.g.,
dissection, side-branch occlusion) and not influenced by
platelet-receptor inhibition, while other events that do
involve angiographically visible thrombus (e.g., thrombus
formation, embolization) do not occur sufficiently frequently
or are not modulated to a sufficient degree by platelet GP
IIb/IIIa inhibition to make the aggregate reduction statis-
tically significant. Interestingly, inspection of our data does
not suggest that eptifibatide has any greater benefit in
preventing “thrombotic” complications than in preventing
“mechanical” complications.
This study does not provide insight into the specific
mechanism by which eptifibatide prevents CK-MB eleva-
tion in patients with uncomplicated coronary interventions.
It may act after the intervention to prevent platelet deposi-
tion on the traumatized lesion and subsequent embolization
of platelet thrombi (13). Alternatively, it may prevent the
occurrence of minor angiographic complications not in-
cluded in case report forms in this study. This possibility is
supported by other studies, which report angiographic
complications in 22% of interventions (7).
Implications for practice. There are two implications for
clinical practice from this study. First, eptifibatide’s failure
to prevent angiographic complications during coronary in-
tervention may explain the reluctance of some intervention-
ists to adopt platelet GP IIb/IIIa inhibitors as a uniform
standard of clinical practice. This implies that pharmaco-
logic interventions might be more widely accepted if they
made procedures obviously easier to perform.
Secondly, the results of this study do not support the post
hoc use of eptifibatide to prevent ischemic complications of
complicated interventions. In the ESPRIT trial, if eptifi-
batide given prospectively did not prevent angiographic
complications or their sequelae, it seems unlikely that
eptifibatide started post hoc would be more effective. In
contrast, it appears that eptifibatide may be most beneficial
when used in a prospective fashion. The paradox remains
that the greatest absolute benefit is achieved among patients
in whom the procedure appears to have gone smoothly.
Study limitations. This study is a retrospective analysis of
data obtained prospectively. Reliability of the data concern-
ing angiographic complications may be limited since the
complications were self-reported by the investigators and
not by a core laboratory blinded to treatment. The lack of
statistical significance of eptifibatide effects in the subgroup
of patients with angiographic complications must be viewed
cautiously since the study was not powered to detect
differences in this group.
Analyses of the ESPRIT trial and this study were
performed on an intention-to-treat basis. Some patients in
the placebo arm received “bail-out” eptifibatide. If “bail-out”
eptifibatide had not been allowed or if analyses had been on
a treatment-received basis, a greater eptifibatide effect on
angiographic complications might have been observed.
Conclusions. Eptifibatide does not significantly decrease
the incidence of angiographic complications during nonur-
gent coronary stent intervention nor the incidence of
CK-MB elevation in patients with angiographic complica-
tions. Most of the benefit of eptifibatide in preventing
CK-MB elevations occurs in patients without angiographic
complications.
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Table 6. Effects of Eptifibatide Observed in This Study, Extrapolated to an Imaginary Cohort of 1,000 Patients
Placebo
(n 5 1,000)
Eptifibatide
(n 5 1,000)
Reduction in CK-MB
Elevations >33 the Normal
Attributable to Eptifibatide
Patients with angiographic complications
Patients 12.2%* of 1,000 5 122 patients 10.2%* of 1,000 5 102 patients
Patients with CK-MB .33 normal 21.6%† of 122 5 26 patients 21.0%† of 102 5 21 patients 26 2 21 5 5
Patients without angiographic complications
Patients 87.8%* of 1,000 5 878 patients 89.8%* of 1,000 5 898 patients
Patients with CK-MB .33 normal 6.8%† of 878 5 60 patients 3.8%† of 898 5 34 patients 60 2 34 5 26
Total 86 2 55 5 31
*Table 4; †Table 6.
CK-MB 5 creatine kinase-myocardial band.
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